Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT00740805
Title Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

non-Hodgkin lymphoma

Advanced Solid Tumor

breast cancer

triple-receptor negative breast cancer

Therapies

Aldoxorubicin + Cyclophosphamide + Veliparib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field